Dapagliflozin in Patients with Chronic Kidney Disease

Pridané:
12.12.2021
Autori: 
Hiddo J.L. Heerspink, Ph.D., Bergur V. Stefánsson, M.D., Ricardo Correa-Rotter, M.D., Glenn M. Chertow, M.D., Tom Greene, Ph.D., Fan-Fan Hou, M.D., Johannes F.E. Mann, M.D., John J.V. McMurray, M.D., Magnus Lindberg, M.Sc., Peter Rossing, M.D., C. David Sjöström, M.D., Roberto D. Toto, M.D., et al., for the DAPA-CKD Trial Committees and Investigators*
Zdroj: 
The NEW ENGLAND JOURNAL of MEDICINE
Tags: 
Cardiovascular disease
Chronic kidney disease
Glucose-lowering therapy
Heart failure